Invex Therapeutics Ltd (IXC.AX)
AUD 0.07
(-10.67%)
AUD 0.07
(-10.67%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.44 Million | -6.86 Million | -3.37 Million | -1.67 Million | -1.6 Million | -230.13 Thousand |
| Net Income | -1.64 Million | -7.74 Million | -3.95 Million | -2.28 Million | -3.36 Million | -232.12 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 137.5 Thousand | 480.54 Thousand | 352.39 Thousand | 562.72 Thousand | 983.39 Thousand | - |
| Change in working capital | -902.15 Thousand | -187.85 Thousand | -124.51 Thousand | 95.68 Thousand | 661.46 Thousand | 1990.00 |
| Other non-cash items | 1 Million | 588.02 Thousand | 348.55 Thousand | -52.73 Thousand | 112.03 Thousand | -1990.00 |
| Investing Cash Flow | - | - | - | - | - | -8191.00 |
| Investments in PPE | - | - | - | - | - | -8191.00 |
| Acquisitions | - | - | - | - | - | -24.57 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | 24.57 Thousand |
| Financing Cash Flow | -14 Million | - | - | 8.09 Million | 15.73 Million | 12.4 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -14 Million | - | - | -553.67 Thousand | -1.81 Million | - |
| Common Stock Issuance | - | - | - | 8.64 Million | 14.43 Million | 12.4 Million |
| Other Financing Activities | -14 Million | - | - | 8.09 Million | 15.73 Million | 37.22 Million |
| Accounts receivables | 238.55 Thousand | -187.85 Thousand | -124.51 Thousand | 95.68 Thousand | 36.48 Thousand | -18.51 Thousand |
| Accounts payables | -1.14 Million | 568.15 Thousand | 345.6 Thousand | -54.33 Thousand | 624.97 Thousand | 20.5 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | -568.15 Thousand | -345.6 Thousand | 54.33 Thousand | - | - |
| Cash at beginning of period | 22.47 Million | 29.33 Million | 32.71 Million | 26.3 Million | 12.17 Million | -24.34 Million |
| Cash at end of period | 6.02 Million | 22.47 Million | 29.33 Million | 32.71 Million | 26.3 Million | 12.17 Million |
| Capital Expenditure | - | - | - | - | - | -8191.00 |
| Effect of forex changes on cash | - | - | - | - | - | 24.34 Million |
| Net cash flow / Change in cash | -16.44 Million | -6.86 Million | -3.37 Million | 6.41 Million | 14.13 Million | 36.51 Million |
| Free Cash Flow | -2.44 Million | -6.86 Million | -3.37 Million | -1.67 Million | -1.6 Million | -238.32 Thousand |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.64 Million | 470.89 Thousand | -2.11 Million | -3.9 Million | -7.74 Million | -1.95 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 19.15 Thousand | 118.34 Thousand | 373.99 Thousand | 480.54 Thousand | - |
| Change in working capital | -902.15 Thousand | 238.55 Thousand | - | -187.85 Thousand | -187.85 Thousand | -93.92 Thousand |
| Other non-cash items | 1 Million | -855.35 Thousand | -322.9 Thousand | 761.93 Thousand | 588.02 Thousand | 380.96 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -14 Million | - | -14 Million | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -14 Million | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -14 Million | - | -14 Million | - | - | - |
| Accounts receivables | 238.55 Thousand | 238.55 Thousand | - | -187.85 Thousand | -187.85 Thousand | -93.92 Thousand |
| Accounts payables | -1.14 Million | - | - | - | 568.15 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | -568.15 Thousand | - |
| Cash at beginning of period | 22.47 Million | 6.15 Million | 22.47 Million | 25.42 Million | 29.33 Million | - |
| Cash at end of period | 6.02 Million | 6.02 Million | 6.15 Million | 22.47 Million | 22.47 Million | -1.47 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -16.44 Million | -126.75 Thousand | -16.31 Million | -2.95 Million | -6.86 Million | -1.47 Million |
| Free Cash Flow | -2.44 Million | -126.75 Thousand | -2.31 Million | -2.95 Million | -6.86 Million | -1.47 Million |
1289
FUND
418550
IMCC
002907
MUX